<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03786497</url>
  </required_header>
  <id_info>
    <org_study_id>PBSF_2018</org_study_id>
    <nct_id>NCT03786497</nct_id>
  </id_info>
  <brief_title>Protecting Brains and Saving Futures</brief_title>
  <acronym>PBSF</acronym>
  <official_title>Protecting Brains and Saving Futures: an Observational Study on Telemedicine Neuroprotection Protocol in Neonatal Intensive Care Unit in Brazil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protecting Brains Saving Futures</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protecting Brains Saving Futures</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple disorders in the neonatal period are associated with high risk of neurological
      impairment. Therapeutic hypothermia is known to be the standard treatment for infants with
      hypoxic ischemic encephalopathy and continuous brain monitoring, including amplitude
      integrated EEG and Near Infrared Spectroscopy, provides useful information for the clinician
      at the bedside. Despite the described benefits, it is estimated that less than 5% of
      Brazilian neonatal centers are well structured and trained to provide therapeutic hypothermia
      or continuous brain monitoring to infants at high risk. In order to reduce the existing gap,
      an advanced telemedicine model is proposed as an alternative to provide neuroprotection
      strategies in developing countries.

      Methods: This is a multi-center prospective observational cohort study conducted in 20
      neonatal intensive care units in Brazil. The inclusion period will be for 5 years. All
      patients will be assessed after hospital discharge between 18 and 24 months of life. Were
      included all infants admitted on the neonatal intensive care units who underwent brain
      monitoring with two channel aEEG/EEG and/or NIRS, presenting inclusion criteria as following:
      hypoxic-ischemic encephalopathy, extreme prematurity, severe peri-intraventricular
      hemorrhage, congenital heart disease, brain malformations, congenital infections, sepsis,
      inborn errors of metabolism, cardiac arrest and also seizures due to various causes.
      Recruitment was ahead of target by eleven months and approvals were obtained allowing
      recruitment to continue to the end of the planned recruitment phase.

      Discussion: The Protecting Brains and Saving Futures study will evaluate the feasibility of
      establishing a telemedicine model to provide remote assistance to neonates at high risk for
      brain injury, evaluation of protocol adherence and patients who underwent TH. Furthermore,
      imaging findings, morbi-mortality and neurodevelopment data will be correlated.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Applicability of telemedicine model for monitored infants</measure>
    <time_frame>up to 96 hours of brain monitoring with aEEG and/or NIRS</time_frame>
    <description>Measured by number of monitored infants per month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Applicability of telemedicine model for recorded remote monitoring</measure>
    <time_frame>up to 96 hours of brain monitoring with aEEG and/or NIRS</time_frame>
    <description>Measured by number of recorded hours of remote monitoring per month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Applicability of telemedicine model for reports issued aEEG/EEG exams</measure>
    <time_frame>up to 96 hours of brain monitoring with aEEG and/or NIRS</time_frame>
    <description>Measured by number of reports issued aEEG/EEG exams with or without the use of NIRS per month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Applicability of telemedicine model for seizures identified</measure>
    <time_frame>up to 96 hours of brain monitoring with aEEG and/or NIRS</time_frame>
    <description>Measured by number of seizures (clinical or subclinical) remotely identified per month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Applicability of telemedicine model for performed TH</measure>
    <time_frame>up to 96 hours of brain monitoring with aEEG and/or NIRS</time_frame>
    <description>Measured by number of patient who performed TH per month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Applicability of telemedicine model for recorded comunications</measure>
    <time_frame>up to 96 hours of brain monitoring with aEEG and/or NIRS</time_frame>
    <description>Measured by number of recorded remote communications between CSI and local team per month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Applicability of telemedicine model for intervention as administration of medicines</measure>
    <time_frame>up to 96 hours of brain monitoring with aEEG and/or NIRS</time_frame>
    <description>Measured by number of administration of anticonvulsivants because of communication per month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Applicability of telemedicine model for intervention as change in therapeutic</measure>
    <time_frame>up to 96 hours of brain monitoring with aEEG and/or NIRS</time_frame>
    <description>Measured by number of changes in ventilatory and hemodynamics parameters and blood transfusion because of communication per month</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Applicability of telemedicine model for clinical case discussion</measure>
    <time_frame>up to 96 hours of brain monitoring with aEEG and/or NIRS</time_frame>
    <description>Measured by number of clinical case discussion videoconference meetings between hospital and monitoring center per month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological brain monitoring findings and imaging exams</measure>
    <time_frame>up to 16 weeks after brain monitoring start</time_frame>
    <description>Association of pathological brain monitoring findings (aEEG/EEG and NIRS) and alterations in imaging exams including cranial magnetic resonance imaging (cMRI) and cranial ultrasonography (cUS) performed during hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological brain monitoring findings with morbi-mortality and length of hospital stay.</measure>
    <time_frame>during the hospitalization (mean 4 weeks)</time_frame>
    <description>Association of pathological brain monitoring findings with morbi-mortality and length of hospital stay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of therapeutic hypothermia</measure>
    <time_frame>during the therapeutic hypothermia and rewarming period (first 84-96 hours of life)</time_frame>
    <description>Adverse effects of therapeutic hypothermia measured by: cardiac arrhythmia, thrombocytopenia and coagulation disorders in general, skin lesion and pulmonary hypertension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of brain monitoring</measure>
    <time_frame>during and 48 hours after the brain monitoring finish (mean 6 days)</time_frame>
    <description>Adverse effects of brain monitoring expressed by skin lesion due to electrode / sensor positioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of pathological brain monitoring findings with neurodevelopment assessment</measure>
    <time_frame>from 18 to 24 months of life</time_frame>
    <description>neurodevelopment assessment by application of the Bayley test between 18 and 24 months of life.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">4800</enrollment>
  <condition>Brain Injuries</condition>
  <condition>Congenital Heart Disease</condition>
  <condition>Newborn</condition>
  <condition>Intraventricular Hemorrhage</condition>
  <condition>Meningitis</condition>
  <condition>Seizures</condition>
  <condition>Sepsis</condition>
  <condition>Hypoxic-Ischemic Encephalopathy</condition>
  <condition>Prematurity</condition>
  <condition>Errors Metabolism, Inborn</condition>
  <condition>Brain Malformation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain monitoring using PBSF protocol</intervention_name>
    <description>Brain function and perfusion will be monitored with two channel aEEG and NIRS by PBSF protocol via telemedicine</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Tertiary care/ neonatal intensive care unit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: All neonates who were admitted at the Neonatal Intensive Care Unit
        (NICU) from centers and monitored by PBSF Telemedicine System including different groups of
        neonates at high risk for brain injuries, as:

          -  Hypoxic Ischemic Encephalopathy (HIE),

          -  Prematurity and extreme low birth weight,

          -  Intraventricular Hemorrhage,

          -  Sepsis,

          -  Meningitis,

          -  Seizures,

          -  Suspected seizures,

          -  Congenital heart disease,

          -  Ventilatory instability associated with hypoxia,

          -  Hyperbilirubinemia,

          -  Central nervous system malformations,

          -  Cardiac arrest,

          -  Inhib Error of Metabolism.

        Exclusion Criteria:

          -  Infants up to 365 days of life or with genetic syndromes, or congenital malformations
             incompatible with life.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rafaela Fabri Rodrigues Pietrobom</name>
      <address>
        <city>SÃ£o Paulo</city>
        <state>SP</state>
        <zip>01221010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Rafaela Pietrobom, MD</last_name>
      <phone>+55 11 949724721</phone>
      <email>rafaela.fabri@pbsf.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2018</study_first_posted>
  <last_update_submitted>December 20, 2018</last_update_submitted>
  <last_update_submitted_qc>December 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Protecting Brains Saving Futures</investigator_affiliation>
    <investigator_full_name>Dr Gabriel Variane</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

